Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this randomized study, patients with early favorable Hodgkin lymphoma showed similar complete remission and survival rates whether receiving 2 or 4 cycles of ABVD and 20 Gy or 30 Gy IFRT, though reduced toxicity was associated with fewer cycles and lower radiation doses.

This case report highlights the importance of suspecting underlying malignancy, such as Hodgkin's lymphoma, in patients with diffuse hair loss and other cutaneous symptoms.

This report describes a case of a man developing hair changes, including Beau's lines and Pohl-Pinkus constrictions, following ABVD chemotherapy.

In this case report, a patient with Hodgkin's disease treated with ABVD chemotherapy became disease-free, and accompanying granuloma annulare skin lesions also improved.

This case report describes a 46-year-old male whose alopecia areata preceded and resolved with treatment for stage IVB classical Hodgkin's lymphoma, highlighting AA as a potential indicator of underlying malignancy, although such cases are rare and not well-characterized.

This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This study found that vinblastine treatment rapidly increased platelet counts in childhood refractory immune thrombocytopenia, providing effective control of bleeding symptoms, although side effects like neuropathic pain were common and resolved with dose adjustments.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This review summarizes the use and neonatal outcomes of chemotherapy during pregnancy, noting its potential for safe use in the second and third trimesters, and reports no new clinical results.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

This article reviews trichoscopic signs of chemotherapy-induced alopecia, including exclamation marks, but reports no new clinical results.

This review discusses various genetic and acquired skin diseases that can affect male fertility, highlighting the clinical management challenges and reports no new research findings.

Scalp hypothermia can prevent chemotherapy-induced hair loss but is not suitable for all patients, and more research is needed to improve prevention methods.

This study observed that 21.6% of oncology patients experienced dermatological side effects from anti-cancer drugs, with hair loss and skin pigmentation changes being the most common.

This document by the AACE and AES provides a 2015 summary of best practices for diagnosing and managing PCOS, emphasizing clinical assessment and treatment options but reports no new clinical results.

This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.

This study found that nearly 40% of Hodgkin’s Lymphoma patients who received Brentuximab Vedotin with AVD chemotherapy experienced persistent alopecia more than two years after treatment, leading to significant psychosocial consequences such as reduced self-confidence and emotional distress.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

This review discusses the toxicities associated with antibody-drug conjugates in breast cancer treatment and proposes strategies for monitoring and managing these adverse effects, but it reports no new clinical results.

This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.

This article reviews antibody drug conjugates for cancer treatment, describing their mechanism, recent approvals, and ongoing research efforts, but reports no new clinical results.

This study found that a mitoxantrone, vincristine, and prednisolone regimen effectively treated recurrent breast cancer with a 70% response rate, though it was associated with significant myelosuppression.

This study found that vinblastine's metabolites show binding affinities for receptors linked to nausea and alopecia, suggesting potential changes to its structure could minimize these side effects during chemotherapy.

This study examined treatments for emesis in young Alexander disease patients, finding that 95% responded positively to valproic acid, which was more effective than anti-reflux medications or cyproheptadine, though some adverse effects require monitoring.

In this case report, researchers observed that the monoclonal antibody bevacizumab may worsen hypothyroidism in patients, as seen in a 60-year-old woman with metastatic duodenal carcinoma. The authors suggest that thyroid function should be monitored when using VEGF inhibitor therapies due to potential adverse effects.

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.

This study reports that adding androgen deprivation therapy to salvage radiation therapy for patients with non-metastatic biochemical recurrence of prostate cancer after radical prostatectomy improves progression-free survival, particularly in those with higher post-prostatectomy PSA levels.

This review describes the clinical presentation, diagnosis, and management of adrenomyeloneuropathy, including rehabilitative therapies and spasticity management, and reports no new clinical results.